Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

976 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety and effectiveness of the fluocinolone acetonide intravitreal implant (ILUVIEN): 3-year results from the European IRISS registry study.
Khoramnia R, Peto T, Koch F, Taylor SR, Castro de Sousa JP, Hill L, Bailey C, Chakravarthy U; ILUVIEN Registry Safety Study (IRISS) Investigators Group. Khoramnia R, et al. Among authors: peto t. Br J Ophthalmol. 2023 Oct;107(10):1502-1508. doi: 10.1136/bjo-2022-321415. Epub 2022 Jul 15. Br J Ophthalmol. 2023. PMID: 35840291 Free PMC article.
A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3.
Rajendram R, Fraser-Bell S, Kaines A, Michaelides M, Hamilton RD, Esposti SD, Peto T, Egan C, Bunce C, Leslie RD, Hykin PG. Rajendram R, et al. Among authors: peto t. Arch Ophthalmol. 2012 Aug;130(8):972-9. doi: 10.1001/archophthalmol.2012.393. Arch Ophthalmol. 2012. PMID: 22491395 Clinical Trial.
A prospective randomised controlled clinical trial comparing a combination of repeated intravitreal Ozurdex and macular laser therapy versus macular laser only in centre-involving diabetic macular oedema (OZLASE study).
Heng LZ, Sivaprasad S, Crosby-Nwaobi R, Saihan Z, Karampelas M, Bunce C, Peto T, Hykin PG. Heng LZ, et al. Among authors: peto t. Br J Ophthalmol. 2016 Jun;100(6):802-7. doi: 10.1136/bjophthalmol-2015-307136. Epub 2015 Oct 15. Br J Ophthalmol. 2016. PMID: 26472406 Clinical Trial.
Evaluation of coronary artery disease as a risk factor for reticular pseudodrusen.
McCarter RV, McKay GJ, Quinn NB, Chakravarthy U, MacGillivray TJ, Robertson G, Pellegrini E, Trucco E, Williams MC, Peto T, Dhillon B, van Beek EJ, Newby DE, Kee F, Young IS, Hogg RE. McCarter RV, et al. Among authors: peto t. Br J Ophthalmol. 2018 Apr;102(4):483-489. doi: 10.1136/bjophthalmol-2017-310526. Epub 2017 Aug 19. Br J Ophthalmol. 2018. PMID: 28822985 Free article.
Intralesional Macular Atrophy in Anti-Vascular Endothelial Growth Factor Therapy for Age-Related Macular Degeneration in the IVAN Trial.
Bailey C, Scott LJ, Rogers CA, Reeves BC, Hamill B, Peto T, Chakravarthy U, Harding SP; writing committee for the IVAN Study Group. Bailey C, et al. Among authors: peto t. Ophthalmology. 2019 Jan;126(1):75-86. doi: 10.1016/j.ophtha.2018.07.013. Epub 2018 Oct 6. Ophthalmology. 2019. PMID: 30301555 Free article. Clinical Trial.
976 results